Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hyperlipoproteinemias

Free Subscription Articles published in Curr Opin Lipidol Retrieve available abstracts of 43 articles: HTML format

Single Articles

April 2024
1. BRUNHAM LR
   Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?
   Curr Opin Lipidol. 2024 Apr 22. doi: 10.1097/MOL.0000000000000938.
   PubMed     Abstract available
   
   
   
2. CIVEIRA F, Martin C, Cenarro A
   APOE and familial hypercholesterolemia.
   Curr Opin Lipidol. 2024 Apr 17. doi: 10.1097/MOL.0000000000000937.
   PubMed     Abstract available
   
   
   February 2024
3. CHAN DC, Watts GF
   ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
   Curr Opin Lipidol. 2024 Feb 20. doi: 10.1097/MOL.0000000000000920.
   PubMed     Abstract available
   
   
   
4. VAN DEN BOSCH SE, Hutten BA, Corpeleijn WE, Kusters DM, et al
   Familial hypercholesterolemia in children and the importance of early treatment.
   Curr Opin Lipidol. 2024 Feb 15. doi: 10.1097/MOL.0000000000000926.
   PubMed     Abstract available
   
   
   
5. ZHANG Y, de Ferranti SD, Moran AE
   Genetic testing for familial hypercholesterolemia.
   Curr Opin Lipidol. 2024 Feb 1. doi: 10.1097/MOL.0000000000000925.
   PubMed     Abstract available
   
   
   December 2023
6. PERERA SD, Hegele RA
   Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
   Curr Opin Lipidol. 2023 Dec 21. doi: 10.1097/MOL.0000000000000916.
   PubMed     Abstract available
   
   
   
7. ROMERO-JIMENEZ MJ, Mansilla-Rodriguez ME, Gutierrez-Cortizo EN
   Predictors of cardiovascular risk in familial hypercholesterolemia.
   Curr Opin Lipidol. 2023;34:272-277.
   PubMed     Abstract available
   
   
   
8. GILLARD BK, Rosales C, Gotto AM Jr, Pownall HJ, et al
   The pathophysiology of excess plasma-free cholesterol.
   Curr Opin Lipidol. 2023;34:278-286.
   PubMed     Abstract available
   
   
   
9. KARALIS DG
   Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease.
   Curr Opin Lipidol. 2023;34:252-258.
   PubMed     Abstract available
   
   
   November 2023
10. ROY G, Drouin-Chartier JP
    Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?
    Curr Opin Lipidol. 2023 Nov 2. doi: 10.1097/MOL.0000000000000908.
    PubMed     Abstract available
    
    
    August 2023
11. CHOUDHARI P, Patni N
    Updates in the management of pediatric dyslipidemia.
    Curr Opin Lipidol. 2023;34:156-161.
    PubMed     Abstract available
    
    
    June 2023
12. GANDA OP
    Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:105-113.
    PubMed     Abstract available
    
    
    
13. WADSTROM BN, Pedersen KM, Wulff AB, Nordestgaard BG, et al
    Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease.
    Curr Opin Lipidol. 2023;34:96-104.
    PubMed     Abstract available
    
    
    April 2023
14. CLARKE SL
    Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
    Curr Opin Lipidol. 2023;34:52-58.
    PubMed     Abstract available
    
    
    March 2023
15. VUORIO A, Raal F, Kovanen PT
    Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19.
    Curr Opin Lipidol. 2023 Mar 10. doi: 10.1097/MOL.0000000000000876.
    PubMed     Abstract available
    
    
    February 2023
16. HANG SMT, Hegele RA, Berberich AJ
    Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia.
    Curr Opin Lipidol. 2023 Feb 2. doi: 10.1097/MOL.0000000000000866.
    PubMed     Abstract available
    
    
    January 2023
17. REIJMAN MD, Defesche JC, Wiegman A
    Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2023 Jan 18. doi: 10.1097/MOL.0000000000000863.
    PubMed     Abstract available
    
    
    December 2022
18. DRON JS
    The clinical utility of polygenic risk scores for combined hyperlipidemia.
    Curr Opin Lipidol. 2022 Dec 28. doi: 10.1097/MOL.0000000000000865.
    PubMed     Abstract available
    
    
    
19. WEI T, Cho L
    Recent lipoprotein(a) trials.
    Curr Opin Lipidol. 2022;33:301-308.
    PubMed     Abstract available
    
    
    
20. TRAMONTANO D, Bini S, D'Erasmo L, Arca M, et al
    Recent Apolipoprotein CIII trials.
    Curr Opin Lipidol. 2022;33:309-318.
    PubMed     Abstract available
    
    
    October 2022
21. TROMP TR, Cuchel M
    New algorithms for treating homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2022 Oct 5. pii: 00041433-990000000-00014.
    PubMed     Abstract available
    
    
    
22. SCIPIONE CA, Cybulsky MI
    Early atherogenesis: new insights from new approaches.
    Curr Opin Lipidol. 2022;33:271-276.
    PubMed     Abstract available
    
    
    August 2022
23. MARTINS J, Rossouw HM, Pillay TS
    How should low-density lipoprotein cholesterol be calculated in 2022?
    Curr Opin Lipidol. 2022;33:237-256.
    PubMed     Abstract available
    
    
    July 2022
24. LEREN TP, Bogsrud MP
    Cascade screening for familial hypercholesterolemia should be organized at a national level.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00004.
    PubMed     Abstract available
    
    
    
25. DURRINGTON PN, Bashir B, Bhatnagar D, Soran H, et al
    Lipoprotein (a) in familial hypercholesterolaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00005.
    PubMed     Abstract available
    
    
    
26. PAQUETTE M, Bernard S, Baass A
    Diagnosis of remnant hyperlipidaemia.
    Curr Opin Lipidol. 2022 Jul 13. pii: 00041433-990000000-00002.
    PubMed     Abstract available
    
    
    December 2021
27. ANTONIAZI L, Arroyo-Olivares R, Mata P, Santos RD, et al
    Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Dec 13. pii: 00041433-900000000-99240.
    PubMed     Abstract available
    
    
    
28. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available
    
    
    
29. MATA P, Alonso R, Perez de Isla L, Badimon L, et al
    Dyslipidemia and aortic valve disease.
    Curr Opin Lipidol. 2021;32:349-354.
    PubMed     Abstract available
    
    
    October 2021
30. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available
    
    
    
31. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available
    
    
    
32. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available
    
    
    September 2021
33. THOMPSON GR
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available
    
    
    August 2021
34. IQBAL Z, Bashir B, Ferdousi M, Kalteniece A, et al
    Lipids and peripheral neuropathy.
    Curr Opin Lipidol. 2021;32:249-257.
    PubMed     Abstract available
    
    
    
35. DRON JS, Hegele RA
    Editorial: Discussing polygenic risk with lipid clinic patients.
    Curr Opin Lipidol. 2021;32:273-275.
    PubMed    
    
    
    April 2021
36. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available
    
    
    
37. PULIPATI VP, Davidson MH
    The clinical black, white, and gray lessons.
    Curr Opin Lipidol. 2021;32:151-156.
    PubMed     Abstract available
    
    
    
38. FONG V, Patel SB
    Recent advances in ABCG5 and ABCG8 variants.
    Curr Opin Lipidol. 2021;32:117-122.
    PubMed     Abstract available
    
    
    February 2021
39. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available
    
    
    
40. BALVERS M, van den Born BH, Levin E, Nieuwdorp M, et al
    Impact drugs targeting cardiometabolic risk on the gut microbiota.
    Curr Opin Lipidol. 2021;32:38-54.
    PubMed     Abstract available
    
    
    October 2020
41. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available
    
    
    
42. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available
    
    
    September 2020
43. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.